Global Oncology Biosimilar Treatment Market || Key players Mylan N.V., F Hoffmann-La Roche, Biogen Inc., Biocon Limited., Novartis AG, Celltrion Healthcare, Plc, Amgen Inc., Pfizer Inc.

Biosimilar are similar to biological medicine which contains active substance from a biological source such as organisms or living cells. They are large, complex structure, possesses potential structural variations and requires large number of clinical trials. It is also referred as bio generics. It is bio therapeutic product which is similar in term of safety, quality and efficacy to the reference bio therapeutic products. Many biologics are also produced using recombinant DNA technology.

Download Free sample copy of this report @
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/1096

Increasing number of collaborative agreement for development and manufacturing for biosimilar are the sources boosting up the target market. Also, growing demand for cost effective treatment for oncology are the major factors serving as the key drivers for the global oncology biosimilar treatment market. Moreover, increasing number of cases for cancer such as breast cancer, cervical cancer, lung cancer, stomach cancer globally, in turn is expected to drive the global oncology biosimilar treatment market over the forecast period. However, manufacturing companies have to launch the product after patent expiration of reference biologic which is expected to limit the market growth. In addition, high manufacturing cost and time required for development of oncology biosimilar, along with high cost for development is expected to restrain the market growth over the forecast period. Increased demand for the healthcare facilities and rapid approval of biosimilar will support the growth of oncology biosimilar market in the near future.
The global oncology biosimilar treatment market has been segmented on the basis of product, cancer, distribution channel, and region. On the basis of product type, the global oncology biosimilar treatment market is consisted of monoclonal antibody, immunomodulators and others. Based on the cancer type, the target market is segmented as blood cancer, breast cancer, lung cancer, cervical cancer, colorectal cancer, kidney cancer, and others. Based on the distribution channel, the target market is comprising of hospital pharmacies, online pharmacies, retail pharmacies.

On the basis of region, the global oncology biosimilar treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America contributes major market share and expected to maintain its dominance over the forecast period. This is attributed to the increasing incidence of cancer, developed healthcare infrastructure, favorable government initiatives, and increasing number of approvals in the region. Robust pipeline by leading market players and launch for the same in US and Canada is expected to drive the market growth in the region. Europe accounts for second-largest revenue share contribution to the global oncology biosimilar treatment market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively. Asia Pacific is expected to witness rapid growth rate over the forecast period. This is attributed owing to increasing number of cancer cases and growing for demand for cost effective treatment in the region.

Key players contributing to global oncology biosimilar treatment market are Mylan N.V., F Hoffmann-La Roche, Biogen Inc., Biocon Limited., Novartis AG, Celltrion Healthcare, Plc, Amgen Inc., Pfizer Inc., Allergan and Teva Pharmaceutical Industries Ltd.

Contact Us:
Mr Alex (Sales Manager)
Prophecy Market Insights
Phone: +91 777 504 9802
+1 860 531 2701
Email: sales@prophecymarketinsights.com

About us:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.

This release was published on openPR.